Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild ‐moderate fibrosis: Results from a real‐world cohort

ConclusionTreatment with PTV/r/OBV/DSV in genotype 1b ‐infected treatment‐naive patients with mild‐moderate fibrosis shows excellent efficacy and safety in real life, similarly to clinical trials. Clinicaltrials.gov, number: NCT03122132.

Source: Liver International - November 12, 2018 Category: Gastroenterology Authors: Marc Puigveh í, Beatriz De Cuenca, Ana Viu, Moisés Diago, Juan Turnes, Francisco Gea, Juan M. Pascasio, Sabela Lens, Joaquín Cabezas, Ester Badia, Antonio Olveira, Rosa M. Morillas, Xavier Torras, Silvia Montoliu, Patricia Cordero, José Tags: ORIGINAL ARTICLE Source Type: research